Where Will AbbVie Be in 5 Years?

A lot has changed for AbbVie (NYSE: ABBV) over the past five years. Notably, the biotech company's Humira, once its biggest growth driver and the world's best-selling drug, lost patent exclusivity in the U.S. in 2023. Despite that setback, AbbVie has produced solid returns over the last half a decade.But can the drugmaker maintain that momentum through 2031? Let's find out how things might unfold for AbbVie over the next five years.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool